Advances in Drug Treatments on Immunomodulatory and Neuroprotective Targets in Multiple Sclerosis

Dear Colleagues,

Multiple Sclerosis (MS) is an immune-mediated demyelinating disease mainly affecting the Central Nervous System (CNS). Advances in comprehending this pathology involve understanding the complex interactions between the different systems, not only nervous and immune (IS) but also the endocrine and metabolic, as well as with the various tissues and organs involved, as well as considering their response to treatments. The response to the different MS treatments is also very heterogeneous, and therefore it is difficult to predict the course of the disease. There is currently no cure for MS, and treatment is mainly based on Disease-Modifying Therapies (DMT) that act on the IS to decrease the relapse rate and the progression of brain lesions, thus limiting neurological deterioration. Finding therapies that work on immunomodulatory and/or neuroprotective targets is an exciting and expanding field of study. Furthermore, identifying subgroups of patients with MS is crucial to understanding the disease's evolution and the response to treatment since subgroups of patients share some characteristics that define variations in the drug effect, diversity of molecular targets, and differences in response to treatment. For these reasons, it is essential to understand the molecular processes further causing MS heterogeneity and varying therapeutic responses, concentrating on immunomodulatory and neuroprotective targets, to advance clinical treatments and better understand the illness.

Dr. Daniel Ortuño-Sahagún
Dr. Lenin Pavon
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.